Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports

被引:23
|
作者
Ueda, Natsumi [1 ]
Umetsu, Ryogo [1 ]
Abe, Junko [1 ,2 ]
Kato, Yamato [1 ]
Nakayama, Yoko [1 ]
Kato, Zenichiro [3 ]
Kinosada, Yasutomi [4 ]
Nakamura, Mitsuhiro [1 ]
机构
[1] Gifu Pharmaceut Univ, Lab Drug Informat, Gifu 5011196, Japan
[2] Med Database Co Ltd, Shibuya Ku, Tokyo 1500011, Japan
[3] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu 5011194, Japan
[4] Gifu Univ, Grad Sch Med, Dept Biomed Informat, Gifu 5011194, Japan
关键词
oseltamivir; abnormal behavior; adverse event report; GENDER-DIFFERENCES; DRUG-REACTIONS; INFLUENZA; DISPROPORTIONALITY; PHARMACOVIGILANCE; CHILDREN; ADHD; PET;
D O I
10.1248/bpb.b15-00253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There have been concerns that oseltamivir causes neuropsychiatric adverse events (NPAEs). We analyzed the association of age and gender with NPAEs in patients treated with oseltamivir using a logistic regression model. NPAE data were obtained from the U.S. Food and Drug Administration Adverse Event Reporting System (2004 to 2013). The lower limit of the reporting odds ratio (ROR) 95% confidence interval (CI) of "abnormal behavior" in Japan, Singapore, and Taiwan was >= 1 The effects of the interaction terms for oseltamivir in male patients aged 10-19 years were statistically significant. The adjusted ROR of "abnormal behavior" was 96.4 (95% CI, 77.5-119.9) in male patients aged 10-19 years treated with osletamivir. In female patients, the results of the likelihood ratio test for "abnormal behavior" were not statistically significant. The adjusted NPAE RORs were increased in male and female patients under the age of 20 years. Oseltamivir use could be associated with "abnormal behavior" in males aged 10-19 years. After considering the causality restraints of the current analysis, further epidemiological studies are recommended.
引用
收藏
页码:1638 / 1644
页数:7
相关论文
共 50 条
  • [21] Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
    Oteo-Alvaro, Angel
    Goicoechea Garcia, Carlos
    Inocencio Sanchez, Alejandra
    Alemany Santamaria, Carlo
    de Diego-Adelino, Javier
    [J]. OSTEOPOROSIS INTERNATIONAL, 2023, 34 (10) : 1799 - 1804
  • [22] Neuropsychiatric and Other Adverse Reactions to Oseltamivir (Tamiflu)
    Brown, J. A.
    Gunja, N.
    Graudins, A.
    [J]. CLINICAL TOXICOLOGY, 2010, 48 (03) : 257 - 257
  • [23] Neuropsychiatric Adverse Events of Varenicline A Systematic Review of Published Reports
    Ahmed, Amir I. A.
    Ali, Abdullah N. A.
    Kramers, Cees
    Harmark, Linda V. D.
    Burger, David M.
    Verhoeven, Willem M. A.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (01) : 55 - 62
  • [24] Evaluation of spontaneous adverse event reports for kidney injury attributed to atezolizumab within the FDA adverse events reporting system
    Zaafan, Ola
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 460 - 460
  • [25] Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with OseltamivirA Comprehensive Review
    Stephen Toovey
    Craig Rayner
    Eric Prinssen
    Tom Chu
    Barbara Donner
    Bharat Thakrar
    Regina Dutkowski
    Gerhard Hoffmann
    Alexander Breidenbach
    Lothar Lindemann
    Ellen Carey
    Lauren Boak
    Ronald Gieschke
    Susan Sacks
    Jonathan Solsky
    Ian Small
    David Ready
    [J]. Drug Safety, 2008, 31 : 1097 - 1114
  • [26] Evaluation of Spontaneous Adverse Event Reports for Muscle Related Adverse Reactions Attributed to Daptomycin within the FDA Adverse Events Reporting System (FAERS)
    Khedr, Ola F.
    Shokr, Hala
    Mekkawy, Mohamed A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 315 - 315
  • [27] Signal generation from spontaneous adverse event reports
    Amery, WK
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 1999, 8 (02) : 147 - 150
  • [28] Geospatial Analysis of Adverse Event Reports
    Semus, Simon
    Azadian, Robert
    Yuen, Nancy
    Burstein, Phillip
    Powell, Gregory
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 100 - 101
  • [29] Adverse events in Covid-19 patients treated with lopinavir/ritonavir: Exploration of US FDA adverse event reporting system (FAERS) reports
    Jahnavi, Yalamanchili
    Neha, Reddy
    Subeesh, Viswam
    Gouri, Nair
    Mazhar, Faizan
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 136 - 136
  • [30] META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
    Murray, Milena M.
    Fakhouri, Lara
    Harpe, Spencer E.
    [J]. DRUGS IN CONTEXT, 2023, 12